<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455401</url>
  </required_header>
  <id_info>
    <org_study_id>2015-024</org_study_id>
    <nct_id>NCT02455401</nct_id>
  </id_info>
  <brief_title>Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery</brief_title>
  <official_title>Effect of Remifentanil on Postoperative Vomiting in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of remifentanil on postoperative vomiting
      in children undergoing strabismus surgery during sevoflurane anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children undergoing strabismus surgery frequently experience postoperative vomiting (POV)
      that results in dehydration, aspiration pneumonia, bleeding, delayed hospital discharge, as
      well as decreased parental satisfaction and an unpleasant experience for the pediatric
      patients. Although administration of perioperative opioids increases POV incidence,
      remifentanil has less affect the incidence of POV than other opioids such as fentanyl.
      However, there are few study that evaluate the effects of remifentanil on the incidence of
      POV. Therefore, the investigators will conducted the study that the effects of remifentanil
      on the incidence of POV in children undergoing strabismus surgery during sevoflurane
      anesthesia. One hundred five children from 3 to 6 yr of age, ASA physical status 1 or 2 were
      assigned randomly selected to one of three groups: high dose remifentanil group (bolus 1.0
      mcg/kg; infusion 0.1 mcg/kg/min), low remifentanil group (bolus 0.5 mcg/kg; infusion 0.1
      mcg/kg/min), or no remifentanil group (no remifentanil administration). Primary endpoint, the
      incidence of POV for 24 hours postoperatively, will be compared between three study groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postoperative vomiting in PACU and surgical ward</measure>
    <time_frame>from extubation to 24 hours</time_frame>
    <description>Vomiting is expulsion of gastric contents. Incidence of vomiting will be compared between the groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain in PACU and surgical ward</measure>
    <time_frame>from extubation to 24 hours</time_frame>
    <description>Postoperative pain will be assessed using Faces Pain Rating Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative emergence agitation</measure>
    <time_frame>from extubation to 24 hours</time_frame>
    <description>Postoperative emergence agitation will be assessed using Pediatric Anesthesia Emergence Delirium.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>high dose remifentanil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: high dose remifentanil will be administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose remifentanil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: low dose remifentanil will be administrated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No remifentanil group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: no remifenatnil will be administrated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose remifentanil</intervention_name>
    <description>Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes</description>
    <arm_group_label>high dose remifentanil group</arm_group_label>
    <other_name>High dose remifentanil (Ultiva,Glaxosmithkline, UK)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose remifentanil</intervention_name>
    <description>Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes</description>
    <arm_group_label>low dose remifentanil group</arm_group_label>
    <other_name>Low dose remifentanil (Ultiva, Glaxosmithkline, UK)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No remifentanil</intervention_name>
    <description>Intervention: no remifentanil will be administrated</description>
    <arm_group_label>No remifentanil group</arm_group_label>
    <other_name>No remifentanil (Ultiva, Glaxosmithkline, UK)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children undergoing elective strabismus surgery under sevoflurane anesthesia

        Exclusion Criteria:

          -  children who experienced postoperative retching or vomiting

          -  children who have taken anti-emetic medications within 24 hours before surgery

          -  children who experienced motion sickness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haeundae paik hospital, inje university</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Ki Hwa Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

